Clinical trial · Observational
Studying Biomarkers in Patients With Pancreatic Cancer
Developing Biomarkers in Pancreatic Cancer
NCT00900003CI-TRIAL-00012961completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| protein analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- pancreatic cancer patients
- description
- pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
- interventionNames
- Genetic: protein analysis
- Other: laboratory biomarker analysis
Primary outcomes (1)
- measure
- Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy
- timeFrame
- following collection of all pancreatic tissue specimens and patient outcome data
- description
- Examine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs given
Secondary outcomes (2)
- measure
- Correlation of pre-treatment markers with survival and recurrence
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria * Any subject with excess tissue collected at time of routine surgery for pancreatic cancer is eligible. * All subjects participating in this protocol will be followed for recurrence, relapse and death from disease
References
Publications (0)
Data not yet available
No reference posted for this study.